Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y2A7

UPID:
NCKP1_HUMAN

ALTERNATIVE NAMES:
Membrane-associated protein HEM-2; p125Nap1

ALTERNATIVE UPACC:
Q9Y2A7; O60329; Q53QN5; Q53S94; Q53Y35

BACKGROUND:
The protein Nck-associated protein 1, with alternative names Membrane-associated protein HEM-2 and p125Nap1, is a key component of the WAVE complex. This complex is vital for the regulation of lamellipodia formation, a process dependent on actin filament reorganization and interaction with the Arp2/3 complex, under the regulation of RAC1. It also plays a significant role in the endocytic trafficking and signaling of BDNF-NTRK2 from early endosomes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Nck-associated protein 1 offers a promising pathway to novel therapeutic interventions. Its critical involvement in cellular structure and signaling pathways makes it a compelling target for therapeutic research in related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.